Trial · NCT06364384
Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma
NCT06364384, Phase 2, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma. Trials, record NCT06364384. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06364384
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma
- NCT number
- NCT06364384
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Conditions
- Rectal Squamous Cell Carcinoma
- Interventions
- PD-1 and CRT
- First posted
- 2024-04-15
- Last updated
- 2026-07-01
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-year tumor-free survival(DFS) | 3 year | The proportion of patients who do not have any of the following events from the beginning of randomization to the end of the first year |
| Secondary | 1-year overall survival (OS) | 1 year | Time interval from the date of randomization to death |
| Secondary | 1-year relapse-free survival (RFS) | 1 year | Time interval from the date of randomization to the onset of recurrence |
| Secondary | 1-year metastasis free survival (DMFS) | 1 year | Time interval from the date of randomization to the occurrence of distant metastases |
| Secondary | Incidence of chemotherapy and immunotherapy-related adverse reactions | through study completion, an average of 6 months | The occurrence of chemotherapy and immune-related side effects during treatment |
| Secondary | Complete response rate (CRR) | through study completion, an average of 6 months | The proportion of the total number of patients with complete response after treatment to the total number of evaluable cases in solid tumor treatment studies |
| Secondary | 1-year stoma-free survival | 1 year | The occurrence of stoma |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06364384
GET https://conductscience.org/api/trials/v1/NCT06364384/registered